Sam Altman is backing a bold gene-editing venture that could one day create embryos free from hereditary disease—and bioethicists are sounding the alarm.

Ambitious Vision, Deep Concerns

OpenAI CEO Sam Altman, together with his husband Oliver Mulherin, is financially supporting a startup called , which seeks to use gene editing to eliminate severe genetic conditions in embryos. According to a published article , the company has already raised US$30 million and is headquartered in San Francisco.

The same report hinted that Preventive's goal is to 'correct devastating genetic conditions' before birth. But critics warn this raises profound ethical dilemmas, especially since editing human embryos is currently illegal in the US, the UK, and many other countries.

Where Could This Research H

See Full Page